Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)

INTRODUCTION: Progestin therapy is the only fertility-sparing treatment option for patients with atypical endometrial hyperplasia (AEH) and endometrial cancer (EC). However, the results of three meta-analyses revealed a high remission rate, as well as an association with a high rate of relapse. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsuhashi, Akira, Kawasaki, Yohei, Hori, Makoto, Fujiwara, Tadami, Hanaoka, Hideki, Shozu, Makio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050341/
https://www.ncbi.nlm.nih.gov/pubmed/32114477
http://dx.doi.org/10.1136/bmjopen-2019-035416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050341/
https://www.ncbi.nlm.nih.gov/pubmed/32114477
http://dx.doi.org/10.1136/bmjopen-2019-035416

Ejemplares similares